Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.

被引：4

作者：

Osipov, Arsen

Popovic, Aleksandra

Hopkins, Alexander

Frampton, Garrett M.

Albacker, Lee A.

Azad, Nilofer Saba

Laheru, Daniel A.

Zheng, Lei

Jaffee, Elizabeth M.

Yarchoan, Mark

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Balimore, MD USA

[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[3] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[4] Fdn Med Inc, Cambridge, MA USA

[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[6] Johns Hopkins Univ Hosp, Baltimore, MD USA

[7] Johns Hopkins Univ, Baltimore, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.2578

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2578

引用

页数：1

共 50 条

[31] Gastrointestinal, pancreatic, and hepatic toxicity profile of CTLA-4 immune checkpoint inhibitors alone and in combination with PD-1/PD-L1 inhibitors: A meta-analysis of clinical trials. [J].

Ali, Faisal ;

Hussain, Maryam R. ;

Deep, Aman ;

Abu-Sbeih, Hamzah ;

Alrifai, Taha ;

Myint, Phyo Thazin ;

Gong, Zimu ;

Kozma, Kelley Elizabeth .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[32] Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators [J].

Le Mercier, Isabelle ;

Lines, J. Louise ;

Noelle, Randolph J. .

FRONTIERS IN IMMUNOLOGY, 2015, 6

[33] Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways [J].

Bewersdorf, Jan Philipp ;

Shallis, Rory M. ;

Zeidan, Amer M. .

BLOOD REVIEWS, 2021, 45

[34] Effects and Mechanisms of Checkpoint Inhibitors (CTLA-4, PD-1 and PD-L1 Inhibitors) as New Immunotherapeutic Agents for Bladder Cancer [J].

Celik, Serdar ;

Altun, Zekiye Sultan ;

Aktas, Safiye .

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2018, 17 (01) :18-25

[35] Tumor Mutational Burden and Response Rate to PD-1 Inhibition [J].

Yarchoan, Mark ;

Hopkins, Alexander ;

Jaffee, Elizabeth M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25) :2500-2501

[36] PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? [J].

Tanvetyanon, Tawee ;

Gray, Jhanelle E. ;

Antonia, Scott J. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (03) :305-312

[37] Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma. [J].

Wang, Daniel Ying ;

Kim, Dae Won ;

Shah, Neil J. ;

Conry, Robert Martin ;

Mehta, Rutika Jitesh ;

Silk, Ann W. ;

Zhou, Alice ;

Voorhees, Amber L. ;

Mckee, Svetlana B. ;

Norrell, Jacqueline ;

Mehnert, Janice M. ;

Puzanov, Igor ;

Gibney, Geoffrey Thomas ;

Rapisuwon, Suthee ;

Eroglu, Zeynep ;

Johnson, Douglas Buckner .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[38] Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. [J].

Selby, Mark ;

Engelhardt, John ;

Lu, Li-Sheng ;

Quigley, Michael ;

Wang, Changyu ;

Chen, Bingliang ;

Korman, Alan J. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

[39] The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors [J].

Nandakumar, Vijayalakshmi ;

Mills, John R. .

CLINICAL CHEMISTRY, 2019, 65 (02) :357-357

[40] Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations [J].

Baksh, Kathryn ;

Weber, Jeffrey .

SEMINARS IN ONCOLOGY, 2015, 42 (03) :363-377

← 1 2 3 4 5 →